April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

By Leigh MacMillan

August 25, 2020

Blocking tumor ‘signals’ and ‘fuel’

Combining two drugs reduced colorectal cancer cell growth in vitro and in an animal model, suggesting the combination may be a promising treatment for patients.

By Leigh MacMillan

March 28, 2019

Cancer’s SOS

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

By Sanjay Mishra

March 13, 2014

A new way to target cancer-driver Ras

Vanderbilt researchers have discovered small molecules that turn off cancerous Ras signals in a new way.

By Leigh MacMillan

July 31, 2013

Factor’s role in long bone development

Insight into how the protein neurofibromin participates in the signaling pathway that produces the body’s long bones has implications for fracture healing in some patients.

By Leigh MacMillan